China biotech flow picks up as Everest seals US$250 million deal
Story summarySovereign wealth funds from Singapore and Abu Dhabi join Chinese state capital as cross-border biotech licensing reaches record highs
Read at South China Morning PostOpens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.